Steve Perrin
About Steve Perrin
Steven Perrin is the President and Chief Scientific Officer with 20 years of drug development experience, previously serving as CEO of Anelixis Therapeutics, Inc.
Company
Steven Perrin currently serves as the President and Chief Scientific Officer of an unspecified company. He was previously the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc., which focuses on the development of therapies for neurodegenerative diseases.
Education and Expertise
Steven Perrin holds a Ph.D. in Biochemistry from Boston University Medical Center. He earned his Bachelor of Science degree from Boston College. His expertise spans over 20 years in drug development, providing him with in-depth knowledge of the pharmaceutical industry.
Professional Background
Steven Perrin began his career as an Associate Professor of Medicine at Boston University Medical Center. He has held research and development positions at several notable organizations, including the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc.
Achievements in ALS Research
Steven Perrin has significantly contributed to ALS research, working with the ALS Therapy Development Institute to create the world’s largest ALS drug development program. His efforts have advanced the understanding and treatment of this debilitating disease.